Fevipiprant, a selective prostaglandin-D2 receptor-2 antagonist, inhibits human group-2 innate lymphoid cell aggregation and function

Publication date: Available online 28 February 2019

Source: Journal of Allergy and Clinical Immunology

Author(s): Clare Hardman, Wentao Chen, Jian Luo, Paul Batty, Yi-Ling Chen, Janina Nahler, Yanqiu Wu, Ian D. Pavord, Veit J. Erpenbeck, David A. Sandham, Luzheng Xue, Graham Ogg

https://ift.tt/2T6rjwT